<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RIVASTIGMINE TARTRATE- rivastigmine tartrateÂ capsuleÂ </strong><br>Watson Laboratories, Inc.<br></p></div>
<h1>Rivastigmine Tartrate Capsules<br>
Issued: October 2007</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_88d71bf2-9434-4488-a2c3-eae5c33a97bb"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_040905f9-f824-4282-975b-fa2324b21051"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Rivastigmine tartrate is a reversible <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor and is known chemically as (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate hydrogen-(2R,3R)-tartrate. Rivastigmine tartrate is commonly referred to in the pharmacological literature as SDZ ENA 713 or ENA 713. It has an empirical formula of C<span class="Sub">14</span>H<span class="Sub">22</span>N<span class="Sub">2</span>O<span class="Sub">2</span>â€¢C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">6</span> (hydrogen tartrate salt â€“ hta salt) and a molecular weight of 400.43 (hta salt). Rivastigmine tartrate is a white to off-white, fine crystalline powder that is very soluble in water, soluble in ethanol and acetonitrile, slightly soluble in n-octanol and very slightly soluble in ethyl acetate. The distribution coefficient at 37Â°C in n-octanol/phosphate buffer solution pH 7 is 3.0.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-1.jpg"></div>
<p>Rivastigmine Tartrate Capsules contain rivastigmine tartrate, equivalent to 1.5, 3, 4.5 and 6 mg of rivastigmine base for oral administration. Inactive ingredients are colloidal silicon dioxide, hypromellose, magnesium stearate, and microcrystalline cellulose. The capsule shells contain gelatin, titanium dioxide, and yellow iron oxide. The 1.5 mg capsule shell also contains red iron oxide. The 4.5 and 6 mg capsule shells also contain red and black iron oxides.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_fb97463a-ff7d-4ed0-8751-d7f43506d9bc"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a59368e1-9cc6-42ab-bf76-5aa9de886fc6"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Pathological changes in <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> of the Alzheimer type and <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> associated with Parkinsonâ€™s disease involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmineâ€™s action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span>. If this proposed mechanism is correct, rivastigmine tartrateâ€™s effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that rivastigmine alters the course of the underlying dementing process. After a 6-mg dose of rivastigmine, anticholinesterase activity is present in CSF for about 10 hours, with a maximum inhibition of about 60% five hours after dosing.</p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies demonstrate that the inhibition of <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> by rivastigmine is not affected by the concomitant administration of memantine, an N-methyl-D-aspartate receptor antagonist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b6c13384-bd5b-4fcf-920d-4210a57203a7"></a><a name="section-3.2"></a><p></p>
<h2>Clinical Trial Data</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> of the Alzheimerâ€™s type</span></p>
<p>The effectiveness of Rivastigmine Tartrate Capsules as a treatment for Alzheimerâ€™s Disease is demonstrated by the results of two randomized, double-blind, placebo-controlled clinical investigations in patients with Alzheimerâ€™s Disease [diagnosed by NINCDS-ADRDA and DSM-IV criteria, Mini-Mental State Examination (MMSE) â‰¥ 10 and â‰¤ 26, and the Global Deterioration Scale (GDS)]. The mean age of patients participating in Rivastigmine Tartrate Capsules trials was 73 years with a range of 41-95. Approximately 59% of patients were women and 41% were men. The racial distribution was Caucasian 87%, Black 4% and Other races 9%.</p>
<p><span class="Bold"><span class="Italics">Study Outcome Measures:</span></span> In each study, the effectiveness of Rivastigmine Tartrate Capsules was evaluated using a dual outcome assessment strategy.</p>
<p>The ability of Rivastigmine Tartrate Capsules to improve cognitive performance was assessed with the cognitive subscale of the Alzheimerâ€™s Disease Assessment Scale (ADAS-cog), a multi-item instrument that has been extensively validated in longitudinal cohorts of Alzheimerâ€™s Disease patients. The ADAS-cog examines selected aspects of cognitive performance including elements of memory, orientation, attention, reasoning, language and praxis. The ADAS-cog scoring range is from 0 to 70, with higher scores indicating greater <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span>. Elderly normal adults may score as low as 0 or 1, but it is not unusual for non-demented adults to score slightly higher.</p>
<p>The patients recruited as participants in each study had mean scores on ADAS-cog of approximately 23 units, with a range from 1 to 61. Experience gained in longitudinal studies of ambulatory patients with mild to moderate Alzheimerâ€™s Disease suggest that they gain 6-12 units a year on the ADAS-cog. Lesser degrees of change, however, are seen in patients with very mild or very advanced disease because the ADAS-cog is not uniformly sensitive to change over the course of the disease. The annualized rate of decline in the placebo patients participating in Rivastigmine Tartrate Capsules trials was approximately 3-8 units per year.</p>
<p>The ability of Rivastigmine Tartrate Capsules to produce an overall clinical effect was assessed using a Clinicianâ€™s Interview-Based Impression of Change (CIBIC) that required the use of caregiver information, the CIBIC-Plus. The CIBIC-Plus is not a single instrument and is not a standardized instrument like the ADAS-cog. Clinical trials for investigational drugs have used a variety of CIBIC formats, each different in terms of depth and structure. As such, results from a CIBIC-Plus reflect clinical experience from the trial or trials in which it was used and can not be compared directly with the results of CIBIC-Plus evaluations from other clinical trials. The CIBIC-Plus used in the Rivastigmine Tartrate Capsules trials was a structured instrument based on a comprehensive evaluation at baseline and subsequent time-points of three domains: patient cognition, behavior and functioning, including assessment of activities of daily living. It represents the assessment of a skilled clinician using validated scales based on his/her observation at interviews conducted separately with the patient and the caregiver familiar with the behavior of the patient over the interval rated. The CIBIC-Plus is scored as a seven point categorical rating, ranging from a score of 1, indicating â€œmarkedly improved,â€? to a score of 4, indicating â€œno changeâ€? to a score of 7, indicating â€œmarked worsening.â€? The CIBIC-Plus has not been systematically compared directly to assessments not using information from caregivers or other global methods.</p>
<p><span class="Bold">U.S. Twenty-Six-Week Study</span></p>
<p>In a study of 26 weeks duration, 699 patients were randomized to either a dose range of 1-4 mg or 6-12 mg of rivastigmine tartrate per day or to placebo, each given in divided doses. The 26-week study was divided into a 12-week forced dose titration phase and a 14-week maintenance phase. The patients in the active treatment arms of the study were maintained at their highest tolerated dose within the respective range.</p>
<p><span class="Bold"><span class="Italics">Effects on the ADAS-cog:</span></span> Figure 1 illustrates the time course for the change from baseline in ADAS-cog scores for all three dose groups over the 26 weeks of the study. At 26 weeks of treatment, the mean differences in the ADAS-cog change scores for the rivastigmine tartrate-treated patients compared to the patients on placebo were 1.9 and 4.9 units for the 1-4 mg and 6-12 mg treatments, respectively. Both treatments were statistically significantly superior to placebo and the 6-12 mg/day range was significantly superior to the 1-4 mg/day range.</p>
<p>Figure 2 illustrates the cumulative percentages of patients from each of the three treatment groups who had attained at least the measure of improvement in ADAS-cog score shown on the X axis. Three change scores, (7-point and 4-point reductions from baseline or no change in score) have been identified for illustrative purposes, and the percent of patients in each group achieving that result is shown in the inset table.</p>
<p>The curves demonstrate that both patients assigned to Rivastigmine Tartrate Capsules and placebo have a wide range of responses, but that the Rivastigmine Tartrate Capsule groups are more likely to show the greater improvements. A curve for an effective treatment would be shifted to the left of the curve for placebo, while an ineffective or deleterious treatment would be superimposed upon, or shifted to the right of the curve for placebo, respectively.</p>
<div class="Figure">
<img alt="Cumulative Percentage of Patients Completing 26 Weeks of Double-blind Treatment " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-2.jpg"><p class="MultiMediaCaption">Figure 2:Â  Cumulative Percentage of Patients Completing 26 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 84%, 1-4 mg 85%, and 6-12 mg 65%.</p>
</div>
<p><span class="Bold"><span class="Italics">Effects on the CIBIC-Plus: </span></span>Figure 3 is a histogram of the frequency distribution of CIBIC-Plus scores attained by patients assigned to each of the three treatment groups who completed 26 weeks of treatment. The mean rivastigmine tartrate-placebo differences for these groups of patients in the mean rating of change from baseline were 0.32 units and 0.35 units for 1-4 mg and 6-12 mg of rivastigmine tartrate, respectively. The mean ratings for the 6-12 mg/day and 1-4 mg/day groups were statistically significantly superior to placebo. The differences between the 6-12 mg/day and the 1-4 mg/day groups were statistically significant.</p>
<div class="Figure"><img alt="Frequuency destribution of CIBIC" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-3.jpg"></div>
<p><span class="Bold">Global Twenty-Six-Week Study</span></p>
<p>In a second study of 26 weeks duration, 725 patients were randomized to either a dose range of 1-4 mg or 6-12 mg of rivastigmine tartrate per day or to placebo, each given in divided doses. The 26-week study was divided into a 12-week forced dose titration phase and a 14-week maintenance phase. The patients in the active treatment arms of the study were maintained at their highest tolerated dose within the respective range.</p>
<p><span class="Bold">Effects on the ADAS-cog:</span> Figure 4 illustrates the time course for the change from baseline in ADAS-cog scores for all three dose groups over the 26 weeks of the study. At 26 weeks of treatment, the mean differences in the ADAS-cog change scores for the rivastigmine tartrate-treated patients compared to the patients on placebo were 0.2 and 2.6 units for the 1-4 mg and 6-12 mg treatments, respectively. The 6-12 mg/day group was statistically significantly superior to placebo, as well as to the 1-4 mg/day group. The difference between the 1-4 mg/day group and placebo was not statistically significant.</p>
<div class="Figure">
<img alt="Figure 4: Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-4.jpg"><p class="MultiMediaCaption">Figure 4: Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment </p>
</div>
<p>Figure 5 illustrates the cumulative percentages of patients from each of the three treatment groups who had attained at least the measure of improvement in ADAS-cog score shown on the X axis. Similar to the U.S. 26-week study, the curves demonstrate that both patients assigned to Rivastigmine Tartrate Capsules and placebo have a wide range of responses, but that the 6-12 mg/day rivastigmine tartrate group is more likely to show the greater improvements.</p>
<div class="Figure">
<img alt="Figure 5: Cumulative Percentage of Patients Completing 26 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 87%, 1-4 mg 86%, and 6-12 mg 67%." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-5.jpg"><p class="MultiMediaCaption">Figure 5: Cumulative Percentage of Patients Completing 26 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 87%, 1-4 mg 86%, and 6-12 mg 67%.</p>
</div>
<p><span class="Bold"><span class="Italics">Effects on the CIBIC-Plus:</span></span> Figure 6 is a histogram of the frequency distribution of CIBIC-Plus scores attained by patients assigned to each of the three treatment groups who completed 26 weeks of treatment. The mean rivastigmine tartrate-placebo differences for these groups of patients for the mean rating of change from baseline were 0.14 units and 0.41 units for 1-4 mg and 6-12 mg of rivastigmine tartrate, respectively. The mean ratings for the 6-12 mg/day group was statistically significantly superior to placebo. The comparison of the mean ratings for the 1-4 mg/day group and placebo group was not statistically significant.</p>
<div class="Figure">
<img alt="Figure 6: Frequency Distribution of CIBIC-Plus Scores at Week 26" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-6.jpg"><p class="MultiMediaCaption">Figure 6: Frequency Distribution of CIBIC-Plus Scores at Week 26</p>
</div>
<p><span class="Bold">U.S. Fixed Dose Study</span></p>
<p>In a study of 26 weeks duration, 702 patients were randomized to doses of 3, 6, or 9 mg/day of rivastigmine tartrate or to placebo, each given in divided doses. The fixed-dose study design, which included a 12-week forced titration phase and a 14-week maintenance phase, led to a high dropout rate in the 9 mg/day group because of poor tolerability. At 26 weeks of treatment, significant differences were observed for the ADAS-cog mean change from baseline for the 9 mg/day and 6 mg/day groups, compared to placebo. No significant differences were observed between any of the rivastigmine tartrate dose groups and placebo for the analysis of the CIBIC-Plus mean rating of change. Although no significant differences were observed between rivastigmine tartrate treatment groups, there was a trend toward numerical superiority with higher doses.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> Associated with Parkinsonâ€™s disease (PDD) </span></span></p>
<p><span class="Italics">International Twenty-Four-Week Study </span></p>
<p>The effectiveness of rivastigmine tartrate as a treatment for <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> associated with Parkinsonâ€™s disease is demonstrated by the results of one randomized, double-blind, placebo-controlled clinical investigation in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, with onset at least 2 years after the initial diagnosis of idiopathic Parkinsonâ€™s disease. The diagnosis of idiopathic Parkinsonâ€™s Disease was based on the United Kingdom Parkinsonâ€™s Disease Society Brain Bank clinical criteria. The diagnosis of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was based on the criteria stipulated under the DSM-IV category â€œDementia Due To Other General Medical Conditionâ€? (code 294.1x), but patients were not required to have a distinctive pattern of cognitive deficits as part of the <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Alternate causes of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> were excluded by clinical history, physical and neurological examination, brain imaging, and relevant blood tests. Patients enrolled in the study had a MMSE score â‰¥ 10 and â‰¤ 24 at entry. The mean age of patients participating in this trial was 72.7 years with a range of 50 to 91. Approximately 35.1% of patients were women and 64.9% of patients were men. The racial distribution was 99.6% Caucasian and Other races 0.4%.</p>
<p><span class="Bold"><span class="Italics">Study Outcome Measures:</span></span> This study used a dual outcome assessment strategy to evaluate the effectiveness of rivastigmine tartrate.</p>
<p>The ability of rivastigmine tartrate to improve cognitive performance was assessed with the ADAS-cog.</p>
<p>The ability of rivastigmine tartrate to produce an overall clinical effect was assessed using the Alzheimerâ€™s Disease Cooperative Study â€“ Clinicianâ€™s Global Impression of Change (ADCS-CGIC). The ADCS-CGIC is a more standardized form of CIBIC-Plus and is also scored as a seven point categorical rating, ranging from a score of 1, indicating "markedly improved," to a score of 4, indicating "no change" to a score of 7, indicating "marked worsening."</p>
<p><span class="Bold"><span class="Italics">Study Results:</span></span> In this study, 541 patients were randomized to a dose range of 3 to 12 mg of rivastigmine tartrate per day or to placebo in a ratio of 2:1, given in divided doses.Â  The 24-week study was divided into a 16-week titration phase and an 8-week maintenance phase.Â  The patients in the active treatment arm of the study were maintained at their highest tolerated dose within the specified dose range.</p>
<p><span class="Bold"><span class="Italics">Effects on the ADAS-cog:</span></span> Figure 7 illustrates the time course for the change from baseline in ADAS-cog scores for both treatment groups over the 24 week study. At 24 weeks of treatment, the mean difference in the ADAS-cog change scores for the rivastigmine tartrate-treated patients compared to the patients on placebo was 3.8 points. This treatment difference was statistically significant in favor of rivastigmine tartrate when compared to placebo.</p>
<div class="Figure">
<img alt="Figure 7: Time course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks Of Treatment" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-7.jpg"><p class="MultiMediaCaption">Figure 7: Time course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks Of Treatment</p>
</div>
<p><span class="Bold"><span class="Italics">Effects on the ADCS-CGIC:</span></span> Figure 8 is a histogram of the distribution of patientsâ€™ scores on the ADCS-CGIC (Alzheimerâ€™s Disease Cooperative Studyâ€”Clinicians Global Impression of Change) at 24 weeks. The mean difference in change scores between the rivastigmine tartrate and placebo groups from baseline was 0.5 points. This difference was statistically significant in favor of rivastigmine tartrate treatment.</p>
<div class="Figure">
<img alt="Figure 8: Distribution of ADCS-CGIC Scores for Patients Completing 24 Weeks Of Treatment" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-8.jpg"><p class="MultiMediaCaption">Figure 8: Distribution of ADCS-CGIC Scores for Patients Completing 24 Weeks Of Treatment</p>
</div>
<p><span class="Bold">Age, Gender and Race:</span> Patientâ€™s age, gender, or race did not predict clinical outcome to Rivastigmine Tartrate Capsules treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5f60ef29-9f5f-4260-b21a-a2769187b2f1"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Rivastigmine is well absorbed with absolute bioavailability of about 40% (3-mg dose). It shows linear pharmacokinetics up to 3 mg BID but is non-linear at higher doses. Doubling the dose from 3 to 6 mg BID results in a 3-fold increase in AUC. The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.</p>
<p><span class="Bold"><span class="Italics">Absorption: </span></span>Rivastigmine is rapidly and completely absorbed. Peak plasma concentrations are reached in approximately 1 hour. Absolute bioavailability after a 3-mg dose is about 36%. Administration of Rivastigmine Tartrate Capsules with food delays absorption (t<span class="Sub">max</span>) by 90 min, lowers C<span class="Sub">max</span> by approximately 30% and increases AUC by approximately 30%.</p>
<p><span class="Bold"><span class="Italics">Distribution:</span></span> Rivastigmine is widely distributed throughout the body with a volume of distribution in the range of 1.8-2.7 L/kg. Rivastigmine penetrates the blood brain barrier, reaching CSF peak concentrations in 1.4-2.6 hours. Mean AUC<span class="Sub">1-12hr</span> ratio of CSF/plasma averaged 40 Â± 0.5% following 1-6 mg BID doses.</p>
<p>Rivastigmine is about 40% bound to plasma proteins at concentrations of 1-400 ng/mL, which cover the therapeutic concentration range. Rivastigmine distributes equally between blood and plasma with a blood-to-plasma partition ratio of 0.9 at concentrations ranging from 1-400 ng/mL.</p>
<p><span class="Bold"><span class="Italics">Metabolism:</span></span> Rivastigmine is rapidly and extensively metabolized, primarily via <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span>-mediated hydrolysis to the decarbamylated metabolite. Based on evidence from <span class="Italics">in vitro</span> and animal studies the major cytochrome P450 isozymes are minimally involved in rivastigmine metabolism. Consistent with these observations is the finding that no drug interactions related to cytochrome P450 have been observed in humans [see <a href="#LINK_adc0671b-b608-40a9-b436-0714827d55e4">Drug-Drug Interactions</a>].</p>
<p><span class="Bold"><span class="Italics">Elimination:</span></span> The major pathway of elimination is via the kidneys. Following administration of <span class="Sub">14</span>C-rivastigmine to 6 healthy volunteers, total recovery of radioactivity over 120 hours was 97% in urine and 0.4% in feces. No parent drug was detected in urine. The sulfate conjugate of the decarbamylated metabolite is the major component excreted in urine and represents 40% of the dose. Mean oral clearance of rivastigmine is 1.8 Â± 0.6 L/min after 6 mg BID.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9fb808ee-60d1-415a-8fb7-089ce1946935"></a><a name="section-3.4"></a><p></p>
<h2>Special Populations</h2>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></span></span>: Following a single 3-mg dose, mean oral clearance of rivastigmine was 60% lower in hepatically impaired patients (n=10, biopsy proven) than in healthy subjects (n=10). After multiple 6 mg BID oral dosing, the mean clearance of rivastigmine was 65% lower in mild (n=7, Child-Pugh score 5-6) and moderate (n=3, Child-Pugh score 7-9) hepatically impaired patients (biopsy proven, <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span>) than in healthy subjects (n=10). Dosage adjustment is not necessary in hepatically impaired patients as the dose of drug is individually titrated to tolerability.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span>:</span></span> Following a single 3-mg dose, mean oral clearance of rivastigmine is 64% lower in moderately impaired renal patients (n=8, GFR=10-50 mL/min) than in healthy subjects (n=10, GFRâ‰¥60 mL/min); CI/F=1.7 L/min (cv=45%) and 4.8 L/min (cv=80%), respectively. In severely impaired renal patients (n=8, GFR&lt;10 mL/min), mean oral clearance of rivastigmine is 43% higher than in healthy subjects (n=10, GFRâ‰¥60 mL/min); CI/F = 6.9 L/min and 4.8 L/min, respectively. For unexplained reasons, the severely impaired renal patients had a higher clearance of rivastigmine than moderately impaired patients. However, dosage adjustment may not be necessary in renally impaired patients as the dose of the drug is individually titrated to tolerability.</p>
<p><span class="Bold"><span class="Italics">Age:</span></span> Following a single 2.5 mg oral dose to elderly volunteers (&gt;60 years of age, n=24) and younger volunteers (n=24), mean oral clearance of rivastigmine was 30% lower in elderly (7 L/min) than in younger subjects (10 L/min).</p>
<p><span class="Bold"><span class="Italics">Gender and Race:</span></span> No specific pharmacokinetic study was conducted to investigate the effect of gender and race on the disposition of Rivastigmine Tartrate Capsules, but a population pharmacokinetic analysis indicates that gender (n=277 males and 348 females) and race (n=575 White, 34 Black, 4 Asian, and 12 Other) did not affect the clearance of Rivastigmine Tartrate Capsules.</p>
<p><span class="Bold"><span class="Italics">Nicotine Use:</span></span> Population PK analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% (n=75 Smokers and 549 <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">Nonsmokers</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_adc0671b-b608-40a9-b436-0714827d55e4"></a><a name="section-3.5"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First"><span class="Bold"><span class="Italics">Effect of Rivastigmine Tartrate Capsules on the Metabolism of Other Drugs: </span></span>Rivastigmine is primarily metabolized through hydrolysis by esterases. Minimal metabolism occurs via the major cytochrome P450 isoenzymes. Based on <span class="Italics">in vitro</span> studies, no pharmacokinetic drug interactions with drugs metabolized by the following isoenzyme systems are expected: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, or CYP2C19.</p>
<p>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. The elevation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time induced by warfarin is not affected by administration of Rivastigmine Tartrate Capsules.</p>
<p><span class="Bold"><span class="Italics">Effect of Other Drugs on the Metabolism of Rivastigmine Tartrate Capsules: </span></span>Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine. Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.</p>
<p>Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), Î²-blockers (n=42), calcium channel blockers (n=75), antidiabetics (n=21), non-steroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). In addition, in clinical trials, no increased risk of clinically relevant untoward effects was observed in patients treated concomitantly with Rivastigmine Tartrate Capsules and these agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_649a98cc-08df-4485-8f04-2fca91f26a4b"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of the Alzheimerâ€™s type.</p>
<p>Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> associated with Parkinsonâ€™s disease.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of Parkinsonâ€™s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention, in patients with an established diagnosis of Parkinsonâ€™s disease. The diagnosis of the <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of Parkinsonâ€™s disease, however, can reliably be made in patients in whom a progressive <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinsonâ€™s disease has been made, and in whom other causes of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> have been ruled out (see <a href="#LINK_b6c13384-bd5b-4fcf-920d-4210a57203a7">CLINICAL PHARMACOLOGY, Clinical Trial Data</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_db25f839-2b5d-4ee4-b467-54c401161321"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Rivastigmine Tartrate Capsules are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to rivastigmine, other carbamate derivatives or other components of the formulation (see <a href="#LINK_040905f9-f824-4282-975b-fa2324b21051">DESCRIPTION</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_f82f6c41-4f6a-4b2a-80a4-38737d0ead7b"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Gastrointestinal Adverse Reactions</span></p>
<p><span class="Bold">Rivastigmine Tartrate Capsules use is associated with significant gastrointestinal adverse reactions, including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. For this reason, patients should always be started at a dose of 1.5 mg BID and titrated to their maintenance dose. If treatment is interrupted for longer than several days, treatment should be reinitiated with the lowest daily dose (see </span><span class="Bold"><a href="#LINK_d3c84a3f-ce2f-496b-b8ca-71023b39bd6a">DOSAGE AND ADMINISTRATION</a></span><span class="Bold">) to reduce the possibility of severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and its potentially serious sequelae (e.g., there has been one postmarketing report of severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> with <span class="product-label-link" type="condition" conceptid="4064575" conceptname="Spontaneous rupture of esophagus">esophageal rupture</span> following inappropriate reinitiation of treatment with a 4.5-mg dose after 8 weeks of treatment interruption).</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>:</span></span><span class="Bold"> In the controlled clinical trials, 47% of the patients treated with a rivastigmine tartrate dose in the therapeutic range of 6-12 mg/day (n=1189) developed <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (compared with 12% in placebo). A total of 31% of rivastigmine tartrate-treated patients developed at least one episode of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (compared with 6% for placebo).The rate of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was higher during the titration phase (24% vs. 3% for placebo) than in the maintenance phase (14% vs. 3% for placebo). The rates were higher in women than men. Five percent of patients discontinued for <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, compared to less than 1% for patients on placebo. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> was severe in 2% of rivastigmine tartrate-treated patients and was rated as mild or moderate each in 14% of patients. The rate of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> was higher during the titration phase (43% vs. 9% for placebo) than in the maintenance phase (17% vs. 4% for placebo).</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span>:</span></span><span class="Bold"> In the controlled trials, approximately 26% of women on high doses of rivastigmine tartrate (greater than 9 mg/day) had <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of equal to or greater than 7% of their baseline weight compared to 6% in the placebo-treated patients. About 18% of the males in the high dose group experienced a similar degree of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> compared to 4% in placebo-treated patients. It is not clear how much of the <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> was associated with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and the <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with the drug.</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>:</span></span> In the controlled clinical trials, of the patients treated with a rivastigmine tartrate dose of 6-12 mg/day, 17% developed <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> compared to 3% of the placebo patients. Neither the time course or the severity of the <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> is known.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcers</span>/<span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Bleeding</span>:</span></span> Because of their pharmacological action, <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. Therefore, patients should be monitored closely for symptoms of active or occult <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, especially those at increased risk for developing <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, e.g., those with a history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). Clinical studies of rivastigmine tartrate have shown no significant increase, relative to placebo, in the incidence of either <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.</p>
<p><span class="Bold">Anesthesia</span></p>
<p>Rivastigmine tartrate as a <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor, is likely to exaggerate succinylcholine-type <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> during anesthesia.</p>
<p><span class="Bold">Cardiovascular Conditions </span></p>
<p>Drugs that increase cholinergic activity may have vagotonic effects on heart rate (e.g., <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>). The potential for this action may be particularly important to patients with â€œsick sinus syndromeâ€? or other supraventricular cardiac conduction conditions. In clinical trials, rivastigmine tartrate was not associated with any increased incidence of cardiovascular adverse events, heart rate or blood pressure changes, or ECG abnormalities. Syncopal episodes have been reported in 3% of patients receiving 6â€“12 mg/day of rivastigmine tartrate, compared to 2% of placebo patients.</p>
<p><span class="Bold">Genitourinary</span></p>
<p>Although this was not observed in clinical trials of Rivastigmine Tartrate Capsules, drugs that increase cholinergic activity may cause urinary obstruction.</p>
<p><span class="Bold">Neurological Conditions</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span> Drugs that increase cholinergic activity are believed to have some potential for causing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. However, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity also may be a manifestation of Alzheimerâ€™s Disease.</p>
<p><span class="Bold">Pulmonary Conditions</span></p>
<p>Like other drugs that increase cholinergic activity, Rivastigmine Tartrate Capsules should be used with care in patients with a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or obstructive pulmonary disease.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_5c14d8b7-4ad2-4e42-8726-27895705f468"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_94395d7a-8ec4-413a-922b-734347c6eecf"></a><a name="section-7.1"></a><p></p>
<h2>Information for Patients and Caregivers</h2>
<p class="First">Caregivers should be advised of the high incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with the use of the drug along with the possibility of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Caregivers should be encouraged to monitor for these adverse events and inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than several days, the next dose should not be administered until they have discussed this with the physician.</p>
<p>Caregivers and patients should be advised that, like other cholinomimetics,Â  Rivastigmine Tartrate Capsules may exacerbate or induce <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>.Â  Worsening in patients with Parkinsonâ€™s disease, including an increased incidence or intensity of <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, has been observed.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_2122e9e5-58c4-4f6a-8a86-e04d88ba2483"></a><a name="section-7.2"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First"><span class="Bold"><span class="Italics">Effect of Rivastigmine Tartrate Capsules on the Metabolism of Other Drugs:</span></span> Rivastigmine is primarily metabolized through hydrolysis by esterases. Minimal metabolism occurs via the major cytochrome P450 isoenzymes. Based on <span class="Italics">in vitro</span> studies, no pharmacokinetic drug interactions with drugs metabolized by the following isoenzyme systems are expected: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, or CYP2C19.</p>
<p>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. The elevation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time induced by warfarin is not affected by administration of Rivastigmine Tartrate Capsules.</p>
<p><span class="Bold"><span class="Italics">Effect of Other Drugs on the Metabolism of Rivastigmine Tartrate Capsules:</span></span> Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine. Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.</p>
<p>Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), Î²-blockers (n=42), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).</p>
<p><span class="Bold"><span class="Italics">Use with Anticholinergics:</span></span> Because of their mechanism of action, <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors have the potential to interfere with the activity of anticholinergic medications.</p>
<p><span class="Bold"><span class="Italics">Use with Cholinomimetics and Other <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">Cholinesterase</span> Inhibitors:</span></span> A synergistic effect may be expected when <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_7357c157-ea38-44c9-9728-0dc3c9e75a74"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In carcinogenicity studies conducted at dose levels up to 1.1 mg-base/kg/day in rats and 1.6 mg-base/kg/day in mice, rivastigmine was not carcinogenic. These dose levels are approximately 0.9 times and 0.7 times the maximum recommended human daily dose of 12 mg/day on a mg/m<span class="Sup">2</span> basis.</p>
<p>Rivastigmine was clastogenic in two <span class="Italics">in vitro</span> assays in the presence, but not the absence, of metabolic activation. It caused structural chromosomal aberrations in V79 Chinese hamster lung cells and both structural and numerical (polyploidy) chromosomal aberrations in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Rivastigmine was not genotoxic in three<span class="Italics"> in vitro</span> assays: the Ames test, the unscheduled DNA synthesis (UDS) test in rat hepatocytes (a test for induction of DNA repair synthesis), and the HGPRT test in V79 Chinese hamster cells. Rivastigmine was not clastogenic in the <span class="Italics">in vivo</span> mouse micronucleus test.</p>
<p>Rivastigmine had no effect on fertility or reproductive performance in the rat at dose levels up to 1.1 mg-base/kg/day. This dose is approximately 0.9 times the maximum recommended human daily dose of 12 mg/per day on a mg/m<span class="Sup">2</span> basis.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_4dbb4741-ccff-4dd3-a303-15a31fe58d8c"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category B:</span></span> Reproduction studies conducted in pregnant rats at doses up to 2.3 mg-base/kg/day (approximately 2 times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) and in pregnant rabbits at doses up to 2.3 mg-base/kg/day (approximately 4 times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Studies in rats showed slightly decreased fetal/pup weights, usually at doses causing some maternal toxicity; decreased weights were seen at doses which were several fold lower than the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. There are no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Rivastigmine Tartrate Capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_040f62e4-b517-4505-956d-9fe060834188"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether rivastigmine is excreted in human breast milk. Rivastigmine Tartrate Capsules have no indication for use in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_5ea3bc9a-c26d-42f8-a779-9d066221e609"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">There are no adequate and well-controlled trials documenting the safety and efficacy of Rivastigmine Tartrate Capsules in any illness occurring in children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_345ea626-796b-4208-be8a-2d9879a3ae86"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> of the Alzheimerâ€™s type</span></p>
<p><span class="Bold">Adverse Events Leading to Discontinuation</span></p>
<p>The rate of discontinuation due to adverse events in controlled clinical trials of Rivastigmine Tartrate Capsules was 15% for patients receiving 6-12 mg/day compared to 5% for patients on placebo during forced weekly dose titration. While on a maintenance dose, the rates were 6% for patients on rivastigmine tartrate compared to 4% for those on placebo.</p>
<p>The most common adverse events leading to discontinuation, defined as those occurring in at least 2% of patients and at twice the incidence seen in placebo patients, are shown in Table 1.</p>
<table frame="void">
<caption><span>Table 1. Most Frequent Adverse Events Leading to Withdrawal from Clinical Trials during Titration and Maintenance in Patients Receiving 6-12 mg/day Rivastigmine Tartrate Capsules Using a Forced Dose Titration</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td valign="top">Â Study Phase</td>
<td class="Rrule" align="center" colspan="2" valign="top">Â Titration</td>
<td class="Lrule Rrule" align="center" colspan="2" valign="top">Â Maintenance</td>
<td class="Lrule" align="center" colspan="2" valign="top">Â Overall</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â </td>
<td class="Botrule" align="center" valign="top">Â Placebo<br><br><br><br>(n=868)</td>
<td class="Botrule Rrule" align="center" valign="top">Â Rivastigmine<br>Tartrate<br>Capsules<br>â‰¥6-12 mg/day<br>(n=1189)</td>
<td class="Botrule Lrule" align="center" valign="top">Â Placebo<br><br><br><br>(n=788)</td>
<td class="Botrule Rrule" align="center" valign="top">Â Rivastigmine<br>Tartrate<br>Capsules<br>â‰¥6-12 mg/day<br>(n=987)</td>
<td class="Botrule Lrule" align="center" valign="top">Â Placebo<br><br><br><br>(n=868)</td>
<td class="Botrule" align="center" valign="top">Â Rivastigmine<br>Tartrate<br>Capsules<br>â‰¥6-12 mg/day<br>(n=1189)</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="top">Â <span class="Bold">Event/%</span><span class="Bold"><br></span><span class="Bold">Discontinuing</span>
</td>
<td class="Toprule" valign="top">Â </td>
<td class="Rrule Toprule" valign="top">Â </td>
<td class="Lrule Toprule" valign="top">Â </td>
<td class="Rrule Toprule" valign="top">Â </td>
<td class="Lrule Toprule" valign="top">Â </td>
<td class="Toprule" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">Â &lt;1</td>
<td class="Rrule" align="center" valign="top">Â 8</td>
<td class="Lrule" align="center" valign="top">Â &lt;1</td>
<td class="Rrule" align="center" valign="top">Â 1</td>
<td class="Lrule" align="center" valign="top">Â 1</td>
<td align="center" valign="top">Â 8</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">Â &lt;1</td>
<td class="Rrule" align="center" valign="top">Â 4</td>
<td class="Lrule" align="center" valign="top">Â &lt;1</td>
<td class="Rrule" align="center" valign="top">Â 1</td>
<td class="Lrule" align="center" valign="top">Â &lt;1</td>
<td align="center" valign="top">Â 5</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" valign="top">Â 0</td>
<td class="Rrule" align="center" valign="top">Â 2</td>
<td class="Lrule" align="center" valign="top">Â &lt;1</td>
<td class="Rrule" align="center" valign="top">Â 1</td>
<td class="Lrule" align="center" valign="top">Â &lt;1</td>
<td align="center" valign="top">Â 3</td>
</tr>
<tr class="Last">
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">Â &lt;1</td>
<td class="Rrule" align="center" valign="top">Â 2</td>
<td class="Lrule" align="center" valign="top">Â &lt;1</td>
<td class="Rrule" align="center" valign="top">Â 1</td>
<td class="Lrule" align="center" valign="top">Â &lt;1</td>
<td align="center" valign="top">Â 2</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Most Frequent Adverse Clinical Events Seen in Association with the Use of Rivastigmine Tartrate Capsules</span></p>
<p>The most common adverse events, defined as those occurring at a frequency of at least 5% and twice the placebo rate, are largely predicted by rivastigmine tartrateâ€™s cholinergic effects. These include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>.</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal Adverse Reactions</span></span></p>
<p>Rivastigmine Tartrate Capsule use is associated with significant <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (see <a href="#LINK_f82f6c41-4f6a-4b2a-80a4-38737d0ead7b">WARNINGS</a>).</p>
<p><span class="Bold">Adverse Events Reported in Controlled Trials</span></p>
<p>Table 2 lists treatment emergent signs and symptoms that were reported in at least 2% of patients in placebo-controlled trials and for which the rate of occurrence was greater for patients treated with rivastigmine tartrate doses of 6-12 mg/day than for those treated with placebo. The prescriber should be aware that these figures cannot be used to predict the frequency of adverse events in the course of usual medical practice when patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis by which to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied.</p>
<p>In general, adverse reactions were less frequent later in the course of treatment.</p>
<p>No systematic effect of race or age could be determined on the incidence of adverse events in the controlled studies. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> were more frequent in women than men.</p>
<table frame="void">
<caption><span>Table 2. Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Rivastigmine Tartrate Capsules (6-12 mg/day) and at a Higher Frequency than Placebo-treated Patients</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<td valign="top">Â <span class="Bold">Body System/Adverse Event</span>
</td>
<td align="center" valign="top">Â <span class="Bold">Placebo</span><span class="Bold"><br></span><span class="Bold"><br></span><span class="Bold"><br></span><span class="Bold">(n=868)</span>
</td>
<td align="center" valign="top">Â <span class="Bold">Rivastigmine Tartrate</span><span class="Bold"><br></span><span class="Bold">Capsules </span><span class="Bold"><br></span><span class="Bold">(6-12 mg/day)</span><span class="Bold"><br></span><span class="Bold">(n=1,189)</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td valign="top">Â <span class="Bold">Percent of Patients with any Adverse Event</span>
</td>
<td align="center" valign="top">Â 79</td>
<td align="center" valign="top">Â 92</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Autonomic Nervous System</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating increased</span></td>
<td align="center" valign="top">Â 1</td>
<td align="center" valign="top">Â 4</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td align="center" valign="top">Â 2</td>
<td align="center" valign="top">Â 3</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Body as a Whole</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  Accidental <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span></td>
<td align="center" valign="top">Â 9</td>
<td align="center" valign="top">Â 10</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center" valign="top">Â 5</td>
<td align="center" valign="top">Â 9</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="top">Â 2</td>
<td align="center" valign="top">Â 6</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td align="center" valign="top">Â 2</td>
<td align="center" valign="top">Â 5</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like Symptoms</td>
<td align="center" valign="top">Â 2</td>
<td align="center" valign="top">Â 3</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decrease</span></td>
<td align="center" valign="top">Â &lt;1</td>
<td align="center" valign="top">Â 3</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, General</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center" valign="top">Â 2</td>
<td align="center" valign="top">Â 3</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Central and Peripheral Nervous System</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">Â 11</td>
<td align="center" valign="top">Â 21</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">Â 12</td>
<td align="center" valign="top">Â 17</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">Â 3</td>
<td align="center" valign="top">Â 5</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center" valign="top">Â 1</td>
<td align="center" valign="top">Â 4</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Gastrointestinal System</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">Â 12</td>
<td align="center" valign="top">Â 47</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">Â 6</td>
<td align="center" valign="top">Â 31</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">Â 11</td>
<td align="center" valign="top">Â 19</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" valign="top">Â 3</td>
<td align="center" valign="top">Â 17</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center" valign="top">Â 6</td>
<td align="center" valign="top">Â 13</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top">Â 4</td>
<td align="center" valign="top">Â 9</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="top">Â 4</td>
<td align="center" valign="top">Â 5</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center" valign="top">Â 2</td>
<td align="center" valign="top">Â 4</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">Eructation</span></td>
<td align="center" valign="top">Â 1</td>
<td align="center" valign="top">Â 2</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Psychiatric Disorders</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="top">Â 7</td>
<td align="center" valign="top">Â 9</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center" valign="top">Â 7</td>
<td align="center" valign="top">Â 8</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center" valign="top">Â 4</td>
<td align="center" valign="top">Â 6</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center" valign="top">Â 3</td>
<td align="center" valign="top">Â 5</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span></td>
<td align="center" valign="top">Â 3</td>
<td align="center" valign="top">Â 4</td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive Reaction</span></td>
<td align="center" valign="top">Â 2</td>
<td align="center" valign="top">Â 3</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Resistance Mechanism Disorders</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></td>
<td align="center" valign="top">Â 6</td>
<td align="center" valign="top">Â 7</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Respiratory System</span>
</td>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â </td>
</tr>
<tr class="Last">
<td valign="top">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center" valign="top">Â 3</td>
<td align="center" valign="top">Â 4</td>
</tr>
</tbody>
</table>
<p>Other adverse events observed at a rate of 2% or more on Rivastigmine Tartrate Capsules 6-12 mg/day but at a greater or equal rate on placebo were <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (general), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (general), <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> Associated with Parkinsonâ€™s disease </span></p>
<p><span class="Bold">Adverse Events leading to discontinuation </span></p>
<p>The rate of discontinuation due to adverse events in the single controlled trial of rivastigmine tartrate was 18.2% for patients receiving 3 to12 mg/day compared to 11.2% for patients on placebo during the 24 week study.</p>
<p>The most frequent adverse events that led to discontinuation from this study, defined as those occurring in at least 1% of patients receiving rivastigmine tartrate and more frequent than those receiving placebo, were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3.6% rivastigmine tartrate vs. 0.6% placebo), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.9% rivastigmine tartrate vs. 0.6% placebo), and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (1.7% rivastigmine tartrate vs. 0.0% placebo).</p>
<p><span class="Bold">Most Frequent Adverse Clinical Events Seen in Association with the Use of Rivastigmine Tartrate</span></p>
<p>The most common adverse events, defined as those occurring at a frequency of at least 5% and twice the placebo rate, are largely predicted by rivastigmine tartrate's cholinergic effects. These include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p><span class="Bold">Adverse Events Reported in Controlled Trials </span></p>
<p>Table 3 lists treatment emergent signs and symptoms that were reported in at least 2% of patients in placebo-controlled trials and for which the rate of occurrence was greater for patients treated with rivastigmine tartrate doses of 3 to12 mg/day than for those treated with placebo. The prescriber should be aware that these figures cannot be used to predict the frequency of adverse events in the course of usual medical practice when patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis by which to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied. In general, adverse reactions were less frequent later in the course of treatment.</p>
<table frame="void">
<caption><span>Table 3. Adverse Events Reported in the Single Controlled Clinical Trial in at Least 2% of Patients Receiving Rivastigmine Tartrate (3 to 12 mg/day) and at a Higher Frequency than Placebo-treated Patients</span></caption>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Botrule" valign="top">Â </td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">Placebo</span>
</td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">Rivastigmine</span><span class="Bold"><br></span><span class="Bold">Tartrate</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Toprule" valign="top">Â <span class="Bold">Body System/Adverse Event</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">(n=179)</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">(3 to 12 mg/day)</span><span class="Bold"><br></span><span class="Bold">(n=362)</span>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="top">Â <span class="Bold">Percent of Patients with any Adverse Event</span>
</td>
<td class="Toprule" align="center" valign="top">Â <span class="Bold">71</span>
</td>
<td class="Toprule" align="center" valign="top">Â <span class="Bold">84</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>
</td>
<td align="center" valign="top">Â </td>
<td valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">Â <span class="Bold">11</span>
</td>
<td align="center" valign="top">Â <span class="Bold">29</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">Â <span class="Bold">2</span>
</td>
<td align="center" valign="top">Â <span class="Bold">17</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">Â <span class="Bold">4</span>
</td>
<td align="center" valign="top">Â <span class="Bold">7</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper abdominal pain</span></td>
<td align="center" valign="top">Â <span class="Bold">1</span>
</td>
<td align="center" valign="top">Â <span class="Bold">4</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">General Disorders and administrative site</span><span class="Bold"><br></span><span class="Bold">conditions</span>
</td>
<td valign="top">Â </td>
<td valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center" valign="top">Â <span class="Bold">3</span>
</td>
<td align="center" valign="top">Â <span class="Bold">4</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="top">Â <span class="Bold">1</span>
</td>
<td align="center" valign="top">Â <span class="Bold">2</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Metabolism and nutritional disorders</span>
</td>
<td valign="top">Â </td>
<td valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" valign="top">Â <span class="Bold">3</span>
</td>
<td align="center" valign="top">Â <span class="Bold">6</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td align="center" valign="top">Â <span class="Bold">1</span>
</td>
<td align="center" valign="top">Â <span class="Bold">2</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system Disorders</span></span>
</td>
<td valign="top">Â </td>
<td valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center" valign="top">Â <span class="Bold">4</span>
</td>
<td align="center" valign="top">Â <span class="Bold">10</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">Â <span class="Bold">1</span>
</td>
<td align="center" valign="top">Â <span class="Bold">6</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">Â <span class="Bold">3</span>
</td>
<td align="center" valign="top">Â <span class="Bold">4</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">Â <span class="Bold">3</span>
</td>
<td align="center" valign="top">Â <span class="Bold">4</span>
</td>
</tr>
<tr>
<td valign="top">Â Parkinsonâ€™s disease (worsening)</td>
<td align="center" valign="top">Â <span class="Bold">1</span>
</td>
<td align="center" valign="top">Â <span class="Bold">3</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></td>
<td align="center" valign="top">Â <span class="Bold">1</span>
</td>
<td align="center" valign="top">Â <span class="Bold">2</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Psychiatric Disorders</span>
</td>
<td valign="top">Â </td>
<td valign="top">Â </td>
</tr>
<tr>
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center" valign="top">Â <span class="Bold">1</span>
</td>
<td align="center" valign="top">Â <span class="Bold">4</span>
</td>
</tr>
<tr class="Last">
<td valign="top">Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="top">Â <span class="Bold">2</span>
</td>
<td align="center" valign="top">Â <span class="Bold">3</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Other Adverse Events Observed During Clinical Trials</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> of the Alzheimerâ€™s Type</span></span></p>
<p>Rivastigmine Tartrate Capsules have been administered to over 5297 individuals during clinical trials worldwide. Of these, 4326 patients have been treated for at least 3 months, 3407 patients have been treated for at least 6 months, 2150 patients have been treated for 1 year, 1250 have been treated for 2 years, and 168 have been treated for over 3 years. With regard to exposure to the highest dose, 2809 patients were exposed to doses of 10-12 mg, 2615 patients treated for 3 months, 2328 patients treated for 6 months, 1378 patients treated for 1 year, 917 patients treated for 2 years, and 129 treated for over 3 years.</p>
<p>Treatment emergent signs and symptoms that occurred during 8 controlled clinical trials and 9 open-label trials in North America, Western Europe, Australia, South Africa, and Japan were recorded as adverse events by the clinical investigators using terminology of their own choosing. To provide an overall estimate of the proportion of individuals having similar types of events, the events were grouped into a smaller number of standardized categories using a modified WHO dictionary, and event frequencies were calculated across all studies. These categories are used in the listing below. The frequencies represent the proportion of 5297 patients from these trials who experienced that event while receiving Rivastigmine Tartrate Capsules. All adverse events occurring in at least 6 patients (approximately 0.1 %) are included, except for those already listed elsewhere in labeling, WHO terms too general to be informative, relatively minor events, or events unlikely to be drug-caused. Events are classified by body system and listed using the following definitions: frequent adverse events - those occurring in at least 1/100 patients; infrequent adverse events - those occurring in 1/100 to 1/1000 patients. These adverse events are not necessarily related to Rivastigmine Tartrate Capsules treatment and in most cases were observed at a similar frequency in placebo-treated patients in the controlled studies.</p>
<p><span class="Bold">Autonomic Nervous System:</span><span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Cold</span> <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, increased saliva.</p>
<p><span class="Bold">Body as a Whole: </span><span class="Italics">Frequent:</span> Accidental <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">Edema periorbital</span> or facial, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span>.</p>
<p><span class="Bold">Cardiovascular System:</span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
<p><span class="Bold">Central and Peripheral Nervous System: </span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">Paresis</span>, <span class="product-label-link" type="condition" conceptid="132342" conceptname="Apraxia">apraxia</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
<p><span class="Bold">Endocrine System:</span><span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Goiter</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
<p><span class="Bold">Gastrointestinal System:</span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">Fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, tenesmus, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>.</p>
<p><span class="Bold">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span>:</span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>.</p>
<p><span class="Bold">Heart Rate and Rhythm Disorders:</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Bold">Liver and Biliary System Disorders:</span><span class="Italics">Infrequent</span>: Abnormal hepatic function, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>.</p>
<p><span class="Bold">Metabolic and Nutritional Disorders: </span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span>:</span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</p>
<p><span class="Bold">Myo-, Endo-, Pericardial and Valve Disorders:</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
<p><span class="Bold">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span>:</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Bold">Psychiatric Disorders:</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">Paranoid reaction</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. <span class="Italics">Infrequent:</span> Abnormal dreaming, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>,<span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, impaired concentration, decreased libido, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p><span class="Bold">Red Blood Cell Disorders:</span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>. <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">Hypochromic anemia</span>.</p>
<p><span class="Bold">Reproductive Disorders (Female &amp; Male):</span><span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span>,<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span>.</p>
<p><span class="Bold">Resistance Mechanism Disorders:</span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<p><span class="Bold">Respiratory System:</span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
<p><span class="Bold">Skin and Appendages:</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> of various kinds (maculopapular, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, bullous, exfoliative, psoriaform, erythematous). <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>.</p>
<p><span class="Bold">Special Senses:</span><span class="Italics">Infrequent:</span> Perversion of taste, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>.</p>
<p><span class="Bold">Urinary System Disorders:</span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">micturition urgency</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p><span class="Bold">Vascular (extracardiac) Disorders:</span><span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysm</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.</p>
<p><span class="Bold">Vision Disorders:</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">Conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p><span class="Bold">White Cell and Resistance Disorders: </span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> Associated with Parkinsonâ€™s Disease</span></span></p>
<p>Rivastigmine Tartrate Capsules have been administered to 485 individuals during clinical trials worldwide. Of these, 413 patients have been treated for at least 3 months, 253 patients have been treated for at least 6 months, and 113 patients have been treated for 1 year.</p>
<p>Additional treatment emergent adverse events in patients with Parkinsonâ€™s disease <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurring in at least 1 patient (approximately 0.3%) are listed below, excluding events that are already listed above for the <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> of the Alzheimerâ€™s type or elsewhere in labeling, WHO terms too general to be informative, relatively minor events, or events unlikely to be drug-caused. Events are classified by body system and listed using the following definitions: frequent adverse events â€“ those occurring in at least 1/100 patients; infrequent adverse events â€“ those occurring in 1/100 to 1/1,000 patients. These adverse events are not necessarily related to Rivastigmine Tartrate Capsules treatment and in most cases were observed at a similar frequency in placebo-treated patients in the controlled studies.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular System:</span></span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>. <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">Sudden cardiac death</span>.</p>
<p><span class="Bold"><span class="Italics">Central and Peripheral Nervous System:</span></span><span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, transient ischemic attack. <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless leg syndrome</span>.</p>
<p><span class="Bold"><span class="Italics">Endocrine System</span></span>: <span class="Italics">Infrequent:</span> Elevated prolactin level.</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal System</span></span><span class="Bold">:</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">Faecaloma</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>.</p>
<p><span class="Bold"><span class="Italics">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span>:</span></span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>. <span class="Italics">Infrequent:</span> Meniereâ€™s disease.</p>
<p><span class="Bold"><span class="Italics">Heart Rate and Rhythm Disorders:</span></span><span class="Italics">Infrequent:</span> Adam-Stokes syndrome.</p>
<p><span class="Bold"><span class="Italics">Liver and Biliary System Disorders:</span></span><span class="Italics">Infrequent:</span> Elevated alkaline phosphatase level, elevated gamma-glutamyltransferase level.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span></span></span>: <span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>. <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Muscle stiffness</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, freezing phenomenon.</p>
<p><span class="Bold"><span class="Italics">Psychiatric Disorders</span></span>: <span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">Delusion</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold"><span class="Italics">Reproductive Disorders (Female &amp; Male)</span></span>: Infrequent: endometrial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="4163232" conceptname="Mastitis">mastitis</span>, <span class="product-label-link" type="condition" conceptid="4052054" conceptname="Benign adenoma of prostate">prostatic adenoma</span>.</p>
<p><span class="Bold"><span class="Italics">Respiratory System</span></span>: <span class="Italics">Frequent</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p>
<p><span class="Bold"><span class="Italics">Urinary System Disorders</span></span>: <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="199075" conceptname="Neurogenic bladder">neurogenic bladder</span>.</p>
<p><span class="Bold">Vascular (extracardiac) Disorders</span>: <span class="Italics">Infrequent</span>: Vasovagal <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>,<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Bold">Vision Disorders</span>: <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="435802" conceptname="Blepharospasm">blepharospasm</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>.</p>
<p><span class="Bold">Post-Introduction Reports</span></p>
<p>Voluntary reports of adverse events temporally associated with Rivastigmine Tartrate Capsules that have been received since market introduction that are not listed above, and that may or may not be causally related to the drug include the following:</p>
<p><span class="Bold"><span class="Italics">Skin Appendages:</span></span> <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_c3dfeb3d-6d16-4d80-ab22-87ee32626250"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Because strategies for the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of any drug.</p>
<p>As rivastigmine tartrate has a short plasma half-life of about one hour and a moderate duration of acetylcholinesterase inhibition of 8-10 hours, it is recommended that in cases of asymptomatic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, no further dose of Rivastigmine Tartrate Capsules should be administered for the next 24 hours.</p>
<p>As in any case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, general supportive measures should be utilized. Overdosage with <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors can result in <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> characterized by severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, collapse and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Increasing <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> is a possibility and may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when coadministered with quaternary anticholinergics such as glycopyrrolate. Due to the short half-life of rivastigmine tartrate, dialysis (hemodialysis, peritoneal dialysis, or hemofiltration) would not be clinically indicated in the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>In <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> accompanied by severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the use of antiemetics should be considered. In a documented case of a 46 mg <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Rivastigmine Tartrate Capsules, the patient experienced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. The patient fully recovered within 24 hours and conservative management was all that was required for treatment.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_d3c84a3f-ce2f-496b-b8ca-71023b39bd6a"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> of the Alzheimerâ€™s type</span></span></p>
<p>The dosage of Rivastigmine Tartrate Capsules shown to be effective in controlled clinical trials is 6-12 mg/day, given as twice-a-day dosing (daily doses of 3 to 6 mg BID). There is evidence from the clinical trials that doses at the higher end of this range may be more beneficial.</p>
<p>The starting dose of Rivastigmine Tartrate Capsules is 1.5 mg twice a day (BID). If this dose is well tolerated, after a minimum of two weeks of treatment, the dose may be increased to 3 mg BID. Subsequent increases to 4.5 mg BID and 6 mg BID should be attempted after a minimum of 2 weeks at the previous dose. If adverse effects (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, loss of appetite) cause intolerance during treatment, the patient should be instructed to discontinue treatment for several doses and then restart at the same or next lower dose level. If treatment is interrupted for longer than several days, treatment should be reinitiated with the lowest daily dose and titrated as described above (see <a href="#LINK_f82f6c41-4f6a-4b2a-80a4-38737d0ead7b">WARNINGS</a>). The maximum dose is 6 mg BID (12 mg/day).</p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> associated with Parkinsonâ€™s Disease</span></span></p>
<p>The dosage of Rivastigmine Tartrate Capsules shown to be effective in the single controlled clinical trial conducted in <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> associated with Parkinsonâ€™s Disease is 3 to 12 mg/day, given as twice-a-day dosing (daily doses of 1.5 to 6 mg BID). In that medical condition, the starting dose of Rivastigmine Tartrate Capsules is 1.5 mg BID; subsequently, the dose may be increased to 3 mg BID and further to 4.5 mg BID and 6 mg BID, based on tolerability, with a minimum of 4 weeks at each dose.</p>
<p>Rivastigmine Tartrate Capsules should be taken with meals in divided doses in the morning and evening.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_3a7b2ba3-b28e-4a87-990d-d17f6f7bf3da"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Rivastigmine Tartrate Capsules equivalent to 1.5 mg, 3 mg, 4.5 mg or 6 mg of rivastigmine base are available as follows:</p>
<p>1.5 mg - orange capsules imprinted with <span class="Bold">WATSON 3208</span>, supplied in bottles of 60 and in unit dose packages of 10 x 10.</p>
<p>3 mg - yellow capsules imprinted with <span class="Bold">WATSON 3209</span>, supplied in bottles of 60 and in unit dose packages of 10 x 10.</p>
<p>4.5 mg - light brown capsules imprinted with <span class="Bold">WATSON 3210</span>, supplied in bottles of 60 and in unit dose packages of 10 x 10.</p>
<p>6 mg - light brown/orange capsules imprinted with <span class="Bold">WATSON 3211</span>, supplied in bottles of 60 and in unit dose packages of 10 x 10.</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold">Mfd. for</span>: Watson Laboratories, Inc.<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Corona, CA 92880 USA</p>
<p><span class="Bold">Mfd. by</span>: Cipla Ltd.<br>Â Â Â Â Â Â Â Â Â Â Â Â Â  Verna, Goa INDIA</p>
<p>Issued:Â  October 2007Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  507 PA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_7c80341e-6451-4477-be28-61f668e55198"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0591-3208-60<br>Rivastigmine<br>Tartrate<br>Capsules<br>1.5 mg</p>
<div class="Figure"><img alt="NDC 0591-3208-60
Rivastigmine
Tartrate
Capsules
1.5 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-9.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_b7484e39-88ab-4cfc-ac17-695d0a304f33"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0591-3209-60<br>Rivastigmine<br>Tartrate<br>Capsules<br>3Â mg</p>
<div class="Figure"><img alt="NDC 0591-3209-60
Rivastigmine
Tartrate
Capsules
3 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-10.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_026ac15f-f423-4513-81d8-05d3d3668dc1"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0591-3210-60<br>Rivastigmine<br>Tartarate<br>Capsules<br>4.5 mg</p>
<div class="Figure"><img alt="vNDC 0591-3210-60
Rivastigmine
Tartarate
Capsules
4.5 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_5d76159e-64dc-4844-932b-df52af7c13c9"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0591-3211-60<br>Rivastigmine<br>Tartarate<br>Capsules<br>6Â mg</p>
<div class="Figure"><img alt="NDC 0591-3211-60
Rivastigmine
Tartarate
Capsules
6 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=36b4f524-90e6-415c-8c0c-8983da2c7fd4&amp;name=rivastigmine-12.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIVASTIGMINE TARTRATEÂ 		
					</strong><br><span class="contentTableReg">rivastigmine tartrate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-3208</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIVASTIGMINE TARTRATE</strong> (RIVASTIGMINE) </td>
<td class="formItem">RIVASTIGMINE TARTRATE</td>
<td class="formItem">1.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;3208</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-3208-44</td>
<td class="formItem">100  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0591-3208-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077129</td>
<td class="formItem">07/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIVASTIGMINE TARTRATEÂ 		
					</strong><br><span class="contentTableReg">rivastigmine tartrate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-3209</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIVASTIGMINE TARTRATE</strong> (RIVASTIGMINE) </td>
<td class="formItem">RIVASTIGMINE TARTRATE</td>
<td class="formItem">3Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;3209</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-3209-44</td>
<td class="formItem">100  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0591-3209-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077129</td>
<td class="formItem">07/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIVASTIGMINE TARTRATEÂ 		
					</strong><br><span class="contentTableReg">rivastigmine tartrate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-3210</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIVASTIGMINE TARTRATE</strong> (RIVASTIGMINE) </td>
<td class="formItem">RIVASTIGMINE TARTRATE</td>
<td class="formItem">4.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;3210</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-3210-44</td>
<td class="formItem">100  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0591-3210-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077129</td>
<td class="formItem">07/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIVASTIGMINE TARTRATEÂ 		
					</strong><br><span class="contentTableReg">rivastigmine tartrate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-3211</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIVASTIGMINE TARTRATE</strong> (RIVASTIGMINE) </td>
<td class="formItem">RIVASTIGMINE TARTRATE</td>
<td class="formItem">6Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brown) ,Â ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Watson;3211</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-3211-44</td>
<td class="formItem">100  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0591-3211-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077129</td>
<td class="formItem">07/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Watson Laboratories, Inc.
							(023932721)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7dccedda-967e-4967-b5c5-e4a90bbb738a</div>
<div>Set id: 36b4f524-90e6-415c-8c0c-8983da2c7fd4</div>
<div>Version: 7</div>
<div>Effective Time: 20100702</div>
</div>
</div>Â <div class="DistributorName">Watson Laboratories, Inc.</div></p>
</body></html>
